iStent *inject*®

Trabecular Micro-Bypass System

Choose iStent *inject*® – First and Foremost

Safe and effective treatment of mild-to-moderate glaucoma[9]

MIGS technologies enable us to intervene earlier and lower IOP without the complications associated with traditional glaucoma therapy.

– Prof. Dr. Manfred Tetz

Why Schlemms Canal Surgery?

There is increasingly broad clinical recognition that glaucoma is a surgical disease where targeted intervention can help restore physiological outflow:

- Increased resistance to aqueous humor outflow through the trabecular meshwork is the primary source of elevated intraocular pressure (IOP) in open-angle glaucoma[1]
- 50 % – 75 % of total resistance to aqueous humor outflow is in the juxtacanalicular tissue of the trabecular meshwork[2]

Micro-Invasive Glaucoma Surgery (MIGS) is an emerging category of glaucoma surgery

MIGS procedures allow for early intervention into glaucoma progression and share the following:[3]

- *Ab interno* microincisional approach
- Minimally traumatic to the target tissue
- Efficacious
- Favourable safety profile
- Rapid recovery with minimal impact to the patients' quality of life

Delivering two preloaded trabecular micro-bypass stents with a single entry, iStent *inject*® optimises the benefits of MIGS

iStent *inject*® reduces IOP by bypassing the primary source of resistance to improve aqueous outflow through the conventional pathway. iStent *inject*® is an elegant procedure for the treatment of OAG:

- Smallest medical device known to be implanted into humans
- Targeted placement of stents helps to restore conventional outflow
- In-vitro perfusion analyses demonstrate increased facility of outflow and IOP reductions with multiple stents[4]
- Both iStent and iStent *inject*® have sufficient capacity to produce steady-state physiological outflow[5,6]



iStent *inject*® is intended to provide safe and effective IOP reduction by addressing OAG at the primary site of resistance to outflow

Outcomes Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication[9]



Mean IOP in 57 phakic patients with iStent *inject*®[1]

- Mean unmedicated IOP decreased by 41% at 18M[9]
- 100 % of eyes DROP FREE at 12M, 98 % of eyes DROP FREE at 18M[9]
- 67 % of eyes ≤ 15mmHg at 12M, 100 % of eyes ≤ 18mmHg at 12M[9]
- No intraoperative or postopertive adverse events observed, related to iStent *inject*®[9]

Smallest medical device known to be implanted into humans



Head

Resides in Schlemm's canal

Thorax

Held by the trabecular meshwork

Flange

Secures placement in the anterior chamber

iStent *inject*®

Trabecular Micro-Bypass System

Preloaded Injector

Engineered with a cam drive to implant two stents

Implantation of two trabecular bypass stents–without the benefit of cataract surgery–has been proven in prospective clinical trials to:

- Lower IOP to < 15mmHg[7]
- Reduce medication burden via a unique two-stent approach[7]

iStent *inject*® as Sole Procedure vs. Two Medications in POAG[7]



Synergy Study[8]

- Multi-center study conducted in Europe
- 99 phakic/pseudophakic eyes
- Uncontrolled on two medications
- Eyes with IOP >18mmHg at six months postop placed on a prostaglandin analogue

At 12-month postoperative visit:

- 72 % of eyes on no medications
- Mean IOP reduction of 34 % vs. medicated screening